Drug Trial Radar · NCT07130175
Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)
Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Dec 31, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Qian FengAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The First Hospital of Zhangjiakou City
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, controlled trial to investigate the efficacy of radiofrequency catheter ablation (RFCA) combined with guideline-directed medical therapy (GDMT) compared to GDMT alone in patients with polymorphic ventricular tachycardia (PMVT) and coexisting heart failure (HF). The study aims to evaluate whether the addition of RFCA can lead to superior improvements in cardiac function, clinical outcomes, and serum biomarkers at a 6-month follow-up.
Conditions
- Polymorphic Ventricular Tachycardia
- Heart Failure
Interventions
Radiofrequency Catheter AblationDevice
An invasive procedure performed under local anesthesia. An electroanatomic mapping system (CARTO 3) was used to identify the arrhythmogenic substrate of the PMVT. Radiofrequency energy was delivered via an irrigated-tip catheter (30-35 W, 43°C, 17 mL/min saline irrigation) to ablate the target sites. The procedural endpoint was the non-inducibility of the clinical arrhythmia. Post-procedure, patients were prescribed amiodarone.
Guideline-Directed Medical Therapy (GDMT)Drug
Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily). Doses were titrated according to patient tolerance and clinical guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Left Ventricular Ejection Fraction (LVEF)Time frame: Baseline, 6 Months Post-treatment
- Change in Left Ventricular End-Diastolic Volume (LVEDV)Time frame: Baseline, 6 Months Post-treatment
- Change in Left Ventricular End-Systolic Volume (LVESV)Time frame: Baseline, 6 Months Post-treatment
- Change in Stroke Volume (SV)Time frame: Baseline, 6 Months Post-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Zhangjiakou City
Zhangjiakou, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.